Drug Discovery Market

1
Drug Discovery Market Trends Forecast Till
2030
sales_at_delvens.com www.delvens.com
2
Drug Discovery Market Trends Forecast Till 2030
Drug Discovery Market, By Drug Type (Small
Molecule Drugs and Biologic Drugs), By Technology
(High Throughput Screening, Pharmacogenomics,
Combinatorial Chemistry, Nanotechnology, and
Other Technologies), By End User (Pharmaceutical
Companies, Contract Research Organizations
(CROs), and region (North America, Europe,
Asia-Pacific, Middle East and Africa and South
America).
Request For Free Sample Report
https//www.delvens.com/get-free-sample/drug-disco
very-market
sales_at_delvens.com
www.delvens.com
3
Market Overview
The global Drug Discovery Market size was
estimated at USD 17.3 billion in 2023 and is
projected to reach USD 56.8 billion in 2030 at a
CAGR of 15.1 during the forecast period
2024-2030. The drug discovery market is
experiencing robust growth driven by several key
factors shaping the pharmaceutical and
biopharmaceutical industries globally. A primary
driver is the increasing incidence of chronic
diseases such as cancer, diabetes, and
cardiovascular disorders, which necessitates the
development of novel and more effective drugs.
This trend is further bolstered by the shift
towards personalized medicine, where treatments
are tailored to individual genetic profiles,
enhancing treatment efficacy and patient
outcomes. Purchase this Report
https//www.delvens.com/checkout/drug-discovery-ma
rket
sales_at_delvens.com
www.delvens.com
4
Key Findings
On the basis of Drug Type, the differentiation
between small molecule drugs and biologic drugs
is pivotal for driving growth in the drug
discovery market. Small molecule drugs,
synthesized chemically, have been foundational in
treating a wide array of diseases due to their
ability to penetrate cell membranes and target
intracellular pathways effectively. On the basis
of Technology, the integration of advanced
technologies such as high throughput screening,
pharmacogenomics, combinatorial chemistry,
nanotechnology, and others is pivotal in driving
the growth of the drug discovery market. High
throughput screening accelerates the
identification of potential drug candidates by
testing large libraries of compounds against
biological targets, thereby expediting the
discovery process. On the basis of type, the
end-user segment comprising pharmaceutical
companies, contract research organizations
(CROs), biotechnology firms, and
academic/research institutions collectively
drives growth in the drug discovery market
through distinct contributions. Pharmaceutical
companies, with their substantial RD investments
and global reach, lead in developing new
therapies and maintaining competitive edges.
sales_at_delvens.com
www.delvens.com
5
Key Findings
The market is also divided into various regions
such as North America, Europe, Asia-Pacific,
South America, and Middle East and Africa. north
america held the largest Drug Discovery Market
share. with substantial RD investments,
government grants, major pharmaceutical presence,
advanced healthcare infrastructure, and
increasing prevalence of chronic diseases,
driving its significant market share. Inquire
Before Buying https//www.delvens.com/Inquire-bef
ore-buying/drug-discovery-market
sales_at_delvens.com
www.delvens.com
6
Competitive Landscape

• Pfizer Inc.
• Novartis AG
• Merck Co., Inc.
• Johnson Johnson
• Roche Holding AG
• Sanofi
• AstraZeneca plc
• GlaxoSmithKline plc
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• AbbVie Inc.

• Amgen Inc.
• Biogen Inc.
• Gilead Sciences, Inc.
• Regeneron Pharmaceuticals, Inc.
• Vertex Pharmaceuticals Incorporated
• Takeda Pharmaceutical Company Limited
• Bayer AG
• Moderna, Inc.
• BioNTech SE

sales_at_delvens.com
www.delvens.com
7
Recent Developments
In October 2022, Verge Genomics, a biotechnology
company at the clinical stage leveraging AI and
human data to revolutionize drug discovery, has
initiated dosing the first participant in its
Phase 1 clinical trial for VRG50635. In August
2022, NGM Bio unveiled the top-line findings from
the CATALINA Phase 2 Trial of NGM621, targeting
patients with geographic atrophy (GA) due to
age-related macular degeneration.
sales_at_delvens.com
www.delvens.com
8
Contact Information
About Us Delvens is a strategic advisory and
consulting company headquartered in New Delhi,
India. The company holds expertise in providing
syndicated research reports, customized research
reports and consulting services. Delvens
qualitative and quantitative data is highly
utilized by each level from niche to major
markets, serving more than 1K prominent companies
by assuring to provide the information on
country, regional and global business
environment. We have a database for more than 45
industries in more than 115 major countries
globally. Contact Us 44-20-3290-6466 1
214-377-1144 sales_at_delvens.com
sales_at_delvens.com
www.delvens.com